(Reuters) – The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc’s Alzheimer’s drug, Aduhelm, that was recently approved by the country’s health regulator.
The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H)
(Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
